Targeted failure of the week. Post No 149. Darapladib

 GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine.

Darapladib had already failed in a late-stage trial for patients with well-treated heart disease.

http://www.reuters.com/article/2014/05/13/us-glaxosmithkline-darapladib-idUSKBN0DT0BU20140513